Drug Type Small molecule drug |
Synonyms lenvatinib, lenvatinib mesilate, Lenvatinib mesilate (JAN) + [18] |
Action antagonists, inhibitors |
Mechanism FGFR1 antagonists(Fibroblast growth factor receptor 1 antagonists), FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists), FGFR3 antagonists(Fibroblast growth factor receptor 3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (13 Feb 2015), |
RegulationAccelerated Approval (United States), Orphan Drug (United States), Priority Review (China), Conditional marketing approval (China), Special Review Project (China), Orphan Drug (Australia), Priority Review (Australia), Breakthrough Therapy (United States), Orphan Drug (Japan) |
Molecular FormulaC22H23ClN4O7S |
InChIKeyHWLFIUUAYLEFCT-UHFFFAOYSA-N |
CAS Registry857890-39-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09920 | Lenvatinib mesylate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Advanced Endometrial Carcinoma | European Union | 25 Jul 2023 | |
Advanced Endometrial Carcinoma | Iceland | 25 Jul 2023 | |
Advanced Endometrial Carcinoma | Liechtenstein | 25 Jul 2023 | |
Advanced Endometrial Carcinoma | Norway | 25 Jul 2023 | |
Recurrent Endometrial Cancer | European Union | 25 Jul 2023 | |
Recurrent Endometrial Cancer | Iceland | 25 Jul 2023 | |
Recurrent Endometrial Cancer | Liechtenstein | 25 Jul 2023 | |
Recurrent Endometrial Cancer | Norway | 25 Jul 2023 | |
Thymus Neoplasms | Japan | 23 Mar 2021 | |
Advanced Renal Cell Carcinoma | European Union | 25 Aug 2016 | |
Advanced Renal Cell Carcinoma | Iceland | 25 Aug 2016 | |
Advanced Renal Cell Carcinoma | Liechtenstein | 25 Aug 2016 | |
Advanced Renal Cell Carcinoma | Norway | 25 Aug 2016 | |
Endometrial Carcinoma | Australia | 28 Jan 2016 | |
Renal Cell Carcinoma | Australia | 28 Jan 2016 | |
Advanced Hepatocellular Carcinoma | European Union | 28 May 2015 | |
Advanced Hepatocellular Carcinoma | Iceland | 28 May 2015 | |
Advanced Hepatocellular Carcinoma | Liechtenstein | 28 May 2015 | |
Advanced Hepatocellular Carcinoma | Norway | 28 May 2015 | |
Differentiated Thyroid Gland Carcinoma | European Union | 28 May 2015 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | China | 28 Oct 2021 | |
Metastatic Esophageal Carcinoma | Phase 3 | United States | 28 Jul 2021 | |
Metastatic Esophageal Carcinoma | Phase 3 | United States | 28 Jul 2021 | |
Metastatic Esophageal Carcinoma | Phase 3 | China | 28 Jul 2021 | |
Metastatic Esophageal Carcinoma | Phase 3 | China | 28 Jul 2021 | |
Metastatic Esophageal Carcinoma | Phase 3 | Japan | 28 Jul 2021 | |
Metastatic Esophageal Carcinoma | Phase 3 | Japan | 28 Jul 2021 | |
Metastatic Esophageal Carcinoma | Phase 3 | Argentina | 28 Jul 2021 | |
Metastatic Esophageal Carcinoma | Phase 3 | Argentina | 28 Jul 2021 | |
Metastatic Esophageal Carcinoma | Phase 3 | Canada | 28 Jul 2021 |
Not Applicable | - | - | fyrziavgns(irggvjbawo) = sblvmeumuw jphxylmslk (azkcqvayvh ) | Positive | 27 Apr 2025 | ||
Phase 2 | 29 | cgvwbpfrrz = fhnzkbasvz jdmejcrcgo (xamupemyxx, fdhosqyfmf - blvemjccgs) View more | - | 16 Apr 2025 | |||
Phase 2 | 43 | xqblapuzpx(zahnulghzw) = ixvgsnjsah vcfkgkokmb (fwprcxjfqn ) | Positive | 26 Mar 2025 | |||
bqunkithds(wflimaqxen) = jbghtypoxt oldkgujhiz (dxctwfdazc ) View more | |||||||
Phase 2 | 11 | mpebttatpx = sorqexhmol rluiwdylda (vamtwqnxzi, brabghckfl - rcgfcuakso) View more | - | 21 Mar 2025 | |||
Not Applicable | 371 | Lenvatinib + anti-PD-1/L1 + interventional therapy | esuonfzbvq(ddguheydpg) = both groups had similar rates of serious adverse events (P = 0.895) nyrkjhxbrn (oaxqfvxfvn ) | Positive | 03 Mar 2025 | ||
Not Applicable | Hepatocellular Carcinoma Adjuvant | 297 | Lenvatinib + TACE | aybqjueiuo(nvnkdizmoi) = zwosqtfdej vpzcceirwv (mdadlgtqjw ) View more | Positive | 01 Mar 2025 | |
(TACE) | aybqjueiuo(nvnkdizmoi) = wlpfmtdors vpzcceirwv (mdadlgtqjw ) View more | ||||||
Phase 3 | 761 | (Part 1 First Course: Pembrolizumab+Chemotherapy+Lenvatinib) | paszzhzvov = tyyccghhom pachjdyeky (xlrgqsyexs, lxpjxqhghu - gkoyovaxbh) View more | - | 21 Feb 2025 | ||
(Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib) | ydwuwwynnr(jnlyatftvt) = qujbtlkyee hgbgvbcfhc (mfdjsltefz, waftdfirzh - oexindktdc) View more | ||||||
Phase 1/2 | Liver Cancer Second line | Third line | - | mxuttzryxg(srqogopauy) = nsinxhcqvf trwksmramr (xsmvmjpist, 7.6 – NR) View more | Positive | 20 Feb 2025 | ||
EASL_LCS2025 Manual | Not Applicable | 64 | ttjykcvlet(flesspwsfb) = rinymjampl zjjsldynnb (nobbhjqfpz ) View more | Positive | 20 Feb 2025 | ||
Phase 2 | 17 | qsdiddqcjs(zctyuebsid) = gbwjdjlqrh oigiyokscx (oeeyjrkzna ) View more | Positive | 13 Feb 2025 |